As we enter May, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.
Table 1. BPIQ company weekly/monthly moves and YTD moves
Category | Weekly Move (5/9-5/13) | YTD Move |
|---|---|---|
All BPIQ Companies | -6.17% | -48.77% |
CAR-T Companies | -1.59% | -52.68% |
Gene Editing Companies | -4.29% | -55.29% |
XBI | -2.18% | -38.73% |
See the biggest moves from last week below:
Don't miss upcoming catalysts.. Get our weekly Catalyst Watchlist Free!
*We never send you spam - unsubscribe anytime
Highlights for the week of 5/9-5/13
Biggest positive move
$BHVN +56.2% Pfizer to Acquire Biohaven Pharmaceuticals & Record reported revenues of $319 million
Biggest negative move
Additional big moves
$VERU +53.7% Veru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use Authorization
$BSGM +50.6% BioSig Technologies, Inc. Issues Shareholder Letter with Corporate Update on Recent Achievements
$TCRX +38.3% TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGCT 25th Annual Meeting
$ASRT +37.5% Assertio Reports First Quarter 2022 Financial Results
$LOGC +34.4% LogicBio Therapeutics Announces FDA Lifts Clinical Hold on SUNRISE Trial in Pediatric Patients with Methylmalonic Acidemia.
$CGEM +23% Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl
$CRBU +22% Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
$BBIO +14% bridgebio announces exclusive license agreement with bristol myers squibb to develop and commercialize bbp-398, a potentially best-in-class shp2 inhibitor, in oncology
$CMPS -11.3% COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults.
$ACIU -12.3% AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology.
$ZYNE -13% Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting
$CUE -15% Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers.
$OBSV -18.3% ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at the 2022 ACOG Annual Clinical and Scientific Meeting.
$BLPH -28.3% Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results
$MREO -31.3% Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency- associated Emphysema.
$RMTI -32% Rockwell Medical Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial
$COGT -37.7% Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results
$EVAX -37.6% Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update
$CDTX -44.2% Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
$VLON -46.6% Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
$TXMD -60% Reverse stock split effective May 6 at 5:01pm
Highlights for next week
To see next week's Big Movers HERE, subscribe. Learn more here.
Watch for quarterly reports from commercial companies
$ADMP
$ALBO
$CMRX
$IMPL
$KALA
$PLX
$RMTI
$TXMD
$PTN
$SYGGF SG016 additional SPRINTER data
$MBIO MB-107 interim Phase 1/2 data
$PASG PBGM01 additional Imagine-1 data
See our Big Movers post to learn about upcoming Movers throughout May and PDUFAs, after subscribing. Learn more here.
Comentarios